Otitis Media – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Otitis Media – Pipeline Review, H2 2017’, provides an overview of the Otitis Media pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Otitis Media

The report reviews pipeline therapeutics for Otitis Media by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Otitis Media therapeutics and enlists all their major and minor projects

The report assesses Otitis Media therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Otitis Media

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Otitis Media

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ContraFect Corp

GlaxoSmithKline Plc

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Novus Therapeutics Inc

Otonomy Inc

Yuhan Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Otitis Media - Overview

Otitis Media - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Otitis Media - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Otitis Media - Companies Involved in Therapeutics Development

ContraFect Corp

GlaxoSmithKline Plc

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Novus Therapeutics Inc

Otonomy Inc

Yuhan Corp

Otitis Media - Drug Profiles

(cholesteryl palmitate + colfosceril palmitate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(dexamethasone acetate + piperacillin sodium + tazobactam sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

betahistine dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-309 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ciprofloxacin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2189242A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazufloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCL-1440 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal (23-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Otitis Media - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Otitis Media - Dormant Projects

Otitis Media - Product Development Milestones

Featured News & Press Releases

Jun 22, 2017: Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO in Acute Otitis Media with Tympanostomy Tubes

Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

May 12, 2017: Otonomy Announces OTIPRIO Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting

Nov 02, 2016: Otonomy Announces Assignment of J Code for OTIPRIO

Oct 07, 2016: Otonomy Holds Investor and Analyst Day and Provides Corporate Update

Oct 04, 2016: Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes

Sep 15, 2016: Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO in Patients with History of Otitis Media Requiring Tympanostomy Tubes

May 20, 2016: Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO

May 16, 2016: Otonomy Announces OTIPRIO Data Presentation and Symposium at Combined Otolaryngology Spring Meetings

Mar 18, 2016: Otonomy Announces Publication of OTIPRIO Phase 3 Clinical Trial Results in JAMA Otolaryngology

Mar 03, 2016: Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes

Mar 02, 2016: Otonomy Announces Commercial Availability of OTIPRIO

Dec 11, 2015: Otonomy Announces FDA Approval of OTIPRIO for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery

Nov 03, 2015: Otonomy Initiates Open-Label Clinical Trial for OTIPRIO in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes

Sep 24, 2015: Otonomy to Present Results for AuriPro Phase 3 Clinical Trials at 2015 AAO-HNSF Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Otitis Media, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Otitis Media – Pipeline by ContraFect Corp, H2 2017

Otitis Media – Pipeline by GlaxoSmithKline Plc, H2 2017

Otitis Media – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017

Otitis Media – Pipeline by Madam Therapeutics BV, H2 2017

Otitis Media – Pipeline by Merck & Co Inc, H2 2017

Otitis Media – Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017

Otitis Media – Pipeline by Novus Therapeutics Inc, H2 2017

Otitis Media – Pipeline by Otonomy Inc, H2 2017

Otitis Media – Pipeline by Yuhan Corp, H2 2017

Otitis Media – Dormant Projects, H2 2017

List of Figures

List of Figures

Number of Products under Development for Otitis Media, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports